Your session is about to expire
← Back to Search
Prosthesis
Knee Replacement Types for Osteoarthritis (MP-Persona Trial)
N/A
Waitlist Available
Led By John Antoniou, MD, PhD
Research Sponsored by Lady Davis Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Males and females between 18 - 80 years at the time of surgery
Be older than 18 years old
Must not have
Patients with inflammatory arthritis, severe neurological conditions, or severe cardiovascular conditions
The presence of previous failed lower extremity arthroplasty or metalwork in situ
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 and 2 years following tka
Awards & highlights
No Placebo-Only Group
Summary
This trial is comparing the clinical effectiveness of two different types of knee replacements, specifically looking at whether or not one provides a better "natural feeling" to the patient.
Who is the study for?
This trial is for adults aged 18-80 with knee osteoarthritis who need a total knee replacement and can follow the study's procedures. They must understand and consent to the study, but cannot join if they have inflammatory arthritis, severe neurological or cardiovascular conditions, previous failed leg surgeries, severe hip OA, or recent leg trauma.
What is being tested?
The trial compares two types of total knee replacements: Zimmer MP Persona (a new design aiming to mimic natural knee motion) versus the traditional Zimmer Persona Knee-PS. The goal is to see which one gives better patient outcomes and more natural-feeling knee movement after surgery.
What are the potential side effects?
Potential side effects from both devices may include pain at the surgery site, swelling, stiffness in the joint area, infection risk around the implant, blood clots in legs or lungs post-surgery and possible allergic reactions to materials.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 80 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have severe arthritis, neurological, or heart conditions.
Select...
I have had a failed leg joint replacement or metal implants in my leg.
Select...
I have severe hip osteoarthritis.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ pre-operative (as baseline) and at 1 and 2 years following tka
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-operative (as baseline) and at 1 and 2 years following tka
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Knee
Secondary study objectives
Adverse Events
EQ-5D-5L Self-Evaluation Questionnaire for Implant Performance
Global Rating of Change (GRC) Self-Evaluation Questionnaire for Implant Performance
+7 moreOther study objectives
Maximum Voluntary Isometric Contractions (MVIC)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Zimmer MP PersonaExperimental Treatment1 Intervention
Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
Group II: Zimmer Persona Knee-PSActive Control1 Intervention
Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
Group III: Healthy ParticipantsActive Control1 Intervention
The control group for the kinematic assessment
Find a Location
Who is running the clinical trial?
McGill UniversityOTHER
410 Previous Clinical Trials
1,018,310 Total Patients Enrolled
1 Trials studying Osteoarthritis
40 Patients Enrolled for Osteoarthritis
Zimmer BiometIndustry Sponsor
375 Previous Clinical Trials
67,855 Total Patients Enrolled
136 Trials studying Osteoarthritis
34,687 Patients Enrolled for Osteoarthritis
Montreal General HospitalOTHER
18 Previous Clinical Trials
9,950 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have severe arthritis, neurological, or heart conditions.I have had a failed leg joint replacement or metal implants in my leg.I am willing and able to follow all study requirements.I have severe hip osteoarthritis.I understand the study's conditions and agree to participate.I need surgery for a leg injury within the year.I have osteoarthritis and am a good candidate for a total knee replacement.I am between 18 and 80 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Zimmer Persona Knee-PS
- Group 2: Healthy Participants
- Group 3: Zimmer MP Persona
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger